Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 zasocitinib trial in moderate to severe hidradenitis suppurativa
NL-OMON59762Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing zasocitinib with placebo (2 arms). Primary endpoint: HiSCR75 at Week 16. Started Jul 2026; status: active, not recruiting.
02
Drugs
zasocitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON59762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59762.